JUL 05, 2020 1:19 PM PDT

New Drug May Reduce Inflammation from COVID-19

WRITTEN BY: Annie Lennon

Scientists from the University of Toronto have identified a new drug candidate that may reduce all kinds of inflammation. In particular, they said that it might be able to target cytokine storms- a potentially deadly sort of inflammatory response that can come by COVID-19 infection. 

Known as TAT CARMIL1, the drug is a combination of two naturally-occurring peptides or small proteins. When combined, they are reportedly able to infiltrate cell membranes and lessen acute inflammatory responses. In particular, the scientists say that the TAT CARMIL1 peptide targets two receptors, attaching itself to the cell’s surface and substrate, where it can then attach itself to other cells too.

In an ex vivo study, the researchers found that the peptide treatment was able to interfere with inflammation-causing cells known as interleukin1, and reduce the degradation of collagen, an abundant protein known as the body’s ‘scaffolding’, by up to 43%. 

If used early enough, they say that the drug may prevent some of the worst damage caused by acute inflammatory responses. Given that one of the primary causes of death from COVID-19 is by cytokine storm- a natural inflammatory response from the body to rid itself of acute infection- the researchers are hopeful it may one day be applied against the virus. 

The scientists are now hoping to test the drug’s effectiveness in in-vitro models. As the peptides are broadly applicable, they can be combined to many drugs. These potentially include treatments for cancer and arthritis, meaning the drug discovery could be useful one day to fight against many different kinds of inflammation. 

Nevertheless, the researchers caution that before we get excited about the drug’s potential prospects, we should wait for further tests. This comes especially as their study so far shows that that the peptide is most effective when applied early on in infection, making it somewhat impractical. 

“In the clinical world, the reality is that you don’t have that luxury,” says Greg Downey, one of the study’s co-authors. 

 

Sources: Genetic Engineering and Biotechnology NewsBusiness Standard

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 12, 2020
Microbiology
Researchers May Have Found a Way to Cure Rotavirus Infections
OCT 12, 2020
Researchers May Have Found a Way to Cure Rotavirus Infections
Rotaviruses are very contagious. They are the most common cause of diarrhea in children and are estimated to cause about ...
OCT 22, 2020
Neuroscience
Placebos Impact Brain Patterns for Emotional Processing
OCT 22, 2020
Placebos Impact Brain Patterns for Emotional Processing
Researchers from Michigan State University have found that placebos reduce markers of emotional distress- even when the ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 20, 2020
Drug Discovery & Development
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
NOV 20, 2020
Cat Parasite Gives Clues on New Drug Targets for Schizophrenia
Researchers from the UK and France have discussed a mechanism of action behind the infamous Toxoplasma gondii  ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...